Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial.

Authors

Sun Young Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Sun Young Kim , Ji Sung Lee , Junho Kang , Satoshi Morita , Young Suk Park , Junichi Sakamoto , Kei Muro , Rui-hua Xu , Tae Won Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).

First Author: Masato Nakamura

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.

First Author: Tae Won Kim

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.

First Author: Zhichao Jiang

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

First Author: Kei Muro